Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs | Suppliers

NSF Explains the Points to Consider when Auditing a Terminally Sterilised Drug Product

Published 12 June 2017 | By NSF Health Sciences Pharma Biotech PBR

When conducting an audit of the terminally sterilized pharmaceutical product process, the essential checklist outlined in this white paper by Maxine Fritz will help.

Available Downloads

NSF Explains the Points to Consider when Auditing a Terminally Sterilised Drug Product